AbbVie Nearing $10.9 Billion Deal to Acquire Apogee Therapeutics
AbbVie is close to finalizing a nearly $11 billion acquisition of anti-inflammatory drug developer Apogee Therapeutics, which would be the company's largest bolt-on deal since 2019.
More World news
- Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class
- AIRO Group Holdings Reaffirms 2026 Revenue Growth Guidance Amid $200 Million Drone Backlog
- Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Raising Uncertainty for Open Source AI Strategy
- Vor Bio and RemeGen Expand Collaboration for Autoimmune Disease Therapy
- EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance
- Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree
- Fed's Schmid Argues Construction Productivity is Key to Housing Affordability Over Interest Rate Cuts
- PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program
- Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures
- Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders